Clinical and Pharmacokinetic Considerations of Novel Formulations of Fentanyl for Breakthrough Cancer Pain

References

• Jandhyala R , Fullarton , JR , BennettMI . Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials . J. Pain Symptom Manage.46 ( 4 ), 573 – 580 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rivera IV , GarridoMJC , VelascoGP , Ximened deEIE , ClavaranaLV . Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain . Adv. Ther.31 ( 1 ), 107 – 117 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith HS . Considerations in selecting rapid-onset opioids for the management of breakthrough pain . J. Pain Res.6 , 189 – 200 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Raj SX , ThronaesM , BrunelliC , HjermstadMJ , KlepstadP , KaasaS . A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic . Support. Care Cancer.22 ( 7 ), 1965 – 1971 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pasternak GW . Pharmacological mechanisms of opioid analgesia . Clin. Neuropharmacol.16 , 1 – 18 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• De Luka A , CouparIM . Insights into the opioid action in the intestinal tract . J. Pharmacol. Exp. Ther.243 , 492 – 500 ( 1987 ).
   PubMedGoogle Scholar
• De Scheper HU , CremoniniF , ParkMI , CamilleriM . Opioids and the gut: pharmacology and current clinical experience . Neurogastroenterol. Motil.16 , 383 – 394 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Gustein HB , AkilH . Opioid analgesics . In:Goodman & Gilman’s The Pharmacological Basis Of Therapeutics ( 11th Edition ). BruntonLL , LasoJS , ParkerKL ( Eds ). McGraw–Hill Companies Inc.NY, USA , 547 – 590 ( 2006 ).
   Google Scholar
• Benyamin R , TrescotAM , DattaSet al. Opioid complications and side effects . Pain Physician11 , S105 – S120 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• De Luca A , CouparIM . Insight into opioid action in the intestinal tract . Pharmacol. Ther.69 ( 2 ), 103 – 115 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Ewe K , UeberschaerB , PressAG . Influence of senna, fibre, and fibre + senna on colonic transit in loperamide-induced constipation . Pharmacology47 ( Suppl. 1 ), 242 – 248 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Evers AS , CrowderCM , BalserJR . General Anesthetics . In:Goodman & Gilman’s The Pharmacological Basis Of Therapeutics ( 11th Edition ). BruntonLL , LasoJS , ParkerKL ( Eds ). McGraw–Hill Companies, Inc.NY, USA , 341 – 368 ( 2006 ).
   Google Scholar
• McLain DA , HugCC . Intravenous fentanyl kinetics . Clin. Pharmacol. Ther.28 , 106 – 114 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Tegeder I , LötschJ , GeisslingerG . Pharmacokinetics of opioids in liver disease . Clin. Pharmacokinet.37 , 17 – 40 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Actiq® package insert . Cephalon, Inc.Frazer, PA, USA ( 2001 ).
   Google Scholar
• Fentora® package insert . Cephalon, Inc.Frazer, PA, USA ( 2011 ).
   Google Scholar
• Onsolis® package insert . Meda Pharmaceuticals , Franklin Township, NJ, USA ( 2012 ).
   Google Scholar
• Abstral® package insert . ProStrakan Inc. , Bridgewater, NJ, USA ( 2012 ).
   Google Scholar
• Subsys® package insert . INSYS Therapeutics, Inc.Phoenix, AZ, USA ( 2012 ).
   Google Scholar
• Roy SD , FlynnGL . Transdermal delivery of narcodicsanalgesics, pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanyl . Pharm. Res.7 , 842 – 847 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Streisand JB , ZhangJ , NiuS , McJamesS , NatteR , PaceNL . Buccal absorption of fentanyl is pH-dependent in dogs . Anesthesiology82 , 759 – 764 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Janssen PA . A review of the chemical features associated with strong morphine-like activity . Br. J. Anaesth.34 , 260 – 268 ( 1962 ).
   PubMed Web of Science ®Google Scholar
• Twycross R , WilcockA . Palliative care formulary ( 3rd Edition ). Oxford , 269 ( 2007 ).
   Google Scholar
• Roy SD , FlynnGL . Solubility behavior of narcotic analgesics in aqueous media, solubilities and dissociation constants of morphine, fentanyl, and sufentanyl . Pharm. Res.6 , 147 – 151 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Roy SD , FlynnGL . Solubility and related physical-chemical properties of narcotic analgesics . Pharm. Res.5 ( 9 ), 580 – 586 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Prodduturi S , SmithGJ , WokovichAM , DoubWH , WestenbergerBJ , BuhseL . Reservoir based fentanyl transdermal drug delivery systems, effect of patch age on drug release and skin permeation . Pharm. Res.26 , 1344 – 1352 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Varvel JR , ShaferSL , HwangSS , CohenPA , StanskiDR . Absorption characteristics of transdermally administered fentanyl . Anesthesiology70 , 928 – 934 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Buxton IL . Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination . In:Goodman & Gilman’s The Pharmacological Basis Of Therapeutics ( 11th Edition ). BruntonLL , LasoJS , ParkerKL ( Eds ). McGraw–Hill Companies, Inc.NY, USA , 1 – 40 ( 2006 ).
   Google Scholar
• Fentanyl Citrate Injection, USP package insert . Hospira, Inc.Lake Forest, IL, USA ( 2008 ).
   Google Scholar
• Labroo RB , PaineMF , ThummelKE , KharaschED . Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4, implications for interindividual variability in disposition, efficacy, and drug interactions . Drug Metab. Disp.25 , 1072 – 1080 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Paine MF , HartHL , LudingtonSS , HainingRL , RettieAE , DeldinDC . The human intestinal cytochrome P450 “pie” . Drug Metab. Disp.34 , 880 – 886 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lazanda® package insert . Depomed Inc.Newark, CA, USA ( 2012 ).
   Google Scholar
• Actiq® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetails .
   Google Scholar
• Fentora® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetail .
   Google Scholar
• Onsolis® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetails .
   Google Scholar
• Abstral® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetails .
   Google Scholar
• Subsys® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetails .
   Google Scholar
• Lazanda® NDA document . www.accessdata.fda.gov/scripts/ceder/drugsatfda/index.cfm?fuceaction=Search.DrugDetails .
   Google Scholar
• Mills S . Pharmaceutical development with focus on pediatric formulations . Presented at:World Health Organization/International Pharmaceutical Federation in Cooperation with the Department of Drug Testing, National Institute for the Control of Pharmaceutical and Biological Products . Beijing, China , 21 – 25June 2010 .
   Google Scholar
• Patra M , SalonenE , TeramaEet al. Under the influence of alcohol: the effect of ethanol and methanol on lipid bilayers . Biophys. J.90 ( 4 ), 1121 – 1135 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Margetts L , SawyerR . Transdermal drug delivery: principles and opioid therapy . Contin. Educ. Anaesth. Crit. Care Pain.7 ( 5 ), 171 – 176 ( 2007 ).
   Google Scholar
• Cutter HS , O’Farrel, Experience with alcohol and the endogenous opioid system in ethanol analgesia . Addict. Behav.12 ( 4 ), 331 – 343 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Campbell VC , TaylorRE , TizabiY . Antinociceptive effects of alcohol and nicotine, involvement of the opioid system . Brain Res.1097 ( 1 ), 71 – 77 ( 2006 ).
   PubMedGoogle Scholar
• Campbell VC , TaylorRE , TizabiY . Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception . Alcohol Clin. Exp. Res.31 ( 8 ), 1435 – 1440 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bourne HB , RossRC , PhilpottNW . Intravenous alcohol in obstetrical labor . Can. Med. Assoc. J.69 , 250 – 254 ( 1953 ).
   PubMed Web of Science ®Google Scholar
• Bukusoglu C , ThalhammerJG , KriegerNR . Analgesia with anesthetic steroids and ethanol . Anesth. Analg.77 ( 1 ), 27 – 31 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Fisher A , WatlingM , SmithA , KnightA . Pharmacokinetic comparisons of three nasalfentanyl formulations: pectin, chitosan and chitosan-poloxamer 188 . Intl. J. Clin. Pharmacol. Ther.48 , 138 – 145 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Parikh N , GoskondaV , ChavanA , DillahaL . Pharmacokinetics and dose proportionality of fentanyl sublingual spray, a single dose 5-way crossover study . Clin. Drug Investig.33 , 391 – 400 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fisher A , WatlingM , SmithA , KnightA . Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 μg inhealthy volunteers . Intl. J. Clin. Pharmacol. Ther.48 , 860 – 867 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Perelman M , FisherA , Watling , SmithA , KnightA . The impact of allergic rhinitis and its treatmenton the pharmacokinetics of nasally administered fentanyl. Intl . J. Clin. Pharmacol. Ther.51 ( 5 ), 349 – 356 ( 2013 ).
   Google Scholar
• Finn A , HillWDC , TargarroI , GeverLN . Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis . J. Pain Res.4 , 245 – 251 ( 2011 ).
   PubMedGoogle Scholar
• Grassin-Delyle S , BuenestadoA , NalineEet al. Intranasal drug delivery, an efficient and non-invasive route for systemic administration focus on opioids . Pharmacol. Ther.134 , 366 – 379 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Pires A , FortunaA , AlvesG , FalcaoA . Intranasal drug delivery, how, why and what for?J. Pharm. Pharmaceut. Sci.12 , 288 – 311 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sonis ST . Mucositis as a biological process, a new hypothesis for the development of chemotherapy-induced stomatotoxicity . Oral Oncol.34 ( 1 ), 39 – 43 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Trotti A , BellmL A , EpsteinJ Bet al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy, a systematic literature review . Radiother. Oncol.66 ( 3 ), 253 – 262 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Bernabei R , GambassiG , LapaneKet al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic assessment of geriatric drug use via epidemiology . JAMA279 , 1877 – 1882 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Carr DB , GoudasLC , BalkEM , BlochR , IoannidisJP , LauJ . Evidence report on the treatment of pain in cancer patients . J. Natl Cancer Inst. Monogr.32 , 23 – 31 ( 2004 ).
   Google Scholar
• Pasero C , MontgomeryR . Pain control, intravenous fentanyl . Am. J. Nurs.102 ( 4 ), 73 – 76 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Lötsch J , WalterC , ParnhamMJ . Pharmacokinetics of non-intravenous formulations of fentanyl . Clin. Pharmacokinet.52 ( 1 ), 23 – 36 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Transmucosal immediate release fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) , 2013 . www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm284717.htm .
   Google Scholar